Radio Medix is a clinical targeted drug developer. It mainly develops innovative targeted radiopharmaceuticals for cancer diagnosis, monitoring and treatment. It is committed to expanding the Targeted Alpha Therapy (TAT) product pipeline and developing clinical radiopharmaceuticals for rare cancers. Recently, Radio Medix announced that it has reached an equity investment agreement with Portland Investment Counsel Inc. for a $40 million Series A financing.
This article is reproduced from: https://www.itjuzi.com/investevent/13598113
This site is for inclusion only, and the copyright belongs to the original author.